title: Neonatal tricyclic antidepressant clomipramine treatment reduces the spike-wave discharge activity of the adult WAG/Rij rat.
abstract: Recently it was revealed that the absence-like epileptic activity of the WAG/Rij (Wistar Albino Glaxo/Rijswijk) rat is associated with depression-like behavioural symptoms. Whether these depressive-like symptoms are accompanying epileptic activity (manifested in spike-wave discharges, SWDs, in the EEG) or whether they are causative for each other are open questions. Neonatally administered tricyclic antidepressant clomipramine is a well characterized animal model of major depression. It evokes behavioural symptoms of depression and changes sleep pattern in normal adult rats. We investigated whether in the WAG/Rij rat the neonatally administered clomipramine would aggravate the depression-like behavioural symptoms and the SWD activity. Male WAG/Rij pups from postnatal day 8 (PD8) to PD21 were treated with clomipramine (20mg/kg) or saline (control animals) twice daily intraperitoneally (i.p.). In the 8 months old rats, sleep parameters and sucrose solution intake (as hedonic index) as well as the SWD activity were measured. While the neonatal clomipramine treatment significantly increased the rapid eye movement sleep (REM) amount and decreased the sucrose preference score, it surprisingly attenuated the adult (8 months old) SWD activity. We concluded that neonatal clomipramine treatment produced aggravation of depression-like symptoms while decreased the SWD activity in the adult (8 months old) WAG/Rij rat.
authors.affiliation: Department of Zoology, University of West Hungary, Savaria Campus, Károlyi Gáspár tér 4, Szombathely 9700, Hungary. zskovacs@ttk.nyme.hu
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Kovács
authors.forename: András
authors.initials: A
authors.lastname: Czurkó
authors.forename: Katalin A
authors.initials: KA
authors.lastname: Kékesi
authors.forename: Gábor
authors.initials: G
authors.lastname: Juhász
mesh_terms: D000200:Action Potentials / Q000187:drug effects* / Q000502:physiology; D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002755:Choice Behavior / Q000187:drug effects; D002997:Clomipramine / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology*; D004195:Disease Models, Animal; D004569:Electroencephalography; D005518:Food Preferences / Q000187:drug effects; D008297:Male; D051381:Rats; D012895:Sleep, REM / Q000187:drug effects; D013395:Sucrose / Q000008:administration & dosage; D013549:Sweetening Agents / Q000008:administration & dosage; D013997:Time Factors; D014851:Wakefulness / Q000187:drug effects
chemical_list: D000929:Antidepressive Agents, Tricyclic; D013549:Sweetening Agents; D013395:Sucrose; D002997:Clomipramine